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Abstract
Background: The risk-benefit ratio of aspirin therapy in prevention of cardiovascular disease
(CVD) remains contentious, especially in type 2 diabetes. This study examined the benefit and harm
of low-dose aspirin (daily dose < 300 mg) in patients with type 2 diabetes.
Methods:  This is a longitudinal observational study with primary and secondary prevention
cohorts based on history of CVD at enrolment. We compared the occurrence of primary
composite (non-fatal myocardial infarction or stroke and vascular death) and secondary endpoints
(upper GI bleeding and haemorrhagic stroke) between aspirin users and non-users between
January 1995 and July 2005.
Results: Of the 6,454 patients (mean follow-up: median [IQR]: 4.7 [4.4] years), usage of aspirin
was 18% (n = 1,034) in the primary prevention cohort (n = 5731) and 81% (n = 585) in the
secondary prevention cohort (n = 723). After adjustment for covariates, in the primary prevention
cohort, aspirin use was associated with a hazard-ratio of 2.07 (95% CI: 1.66, 2.59, p < 0.001) for
primary endpoint. There was no difference in CVD event rate in the secondary prevention cohort.
Overall, aspirin use was associated with a hazard-ratio of 2.2 (1.53, 3.15, p < 0.001) of GI bleeding
and 1.71 (1.00, 2.95, p = 0.051) of haemorrhagic stroke. The absolute risk of aspirin-related GI
bleeding was 10.7 events per 1,000 person-years of treatment.
Conclusion:  In Chinese type 2 diabetic patients, low dose aspirin was associated with a
paradoxical increase in CVD risk in primary prevention and did not confer benefits in secondary
prevention. In addition, the risk of GI bleeding in aspirin users was rather high.
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Background
Type 2 diabetes is associated with 2-3 fold increased risk
of cardiovascular disease (CVD) and is a leading cause of
mortality and morbidity [1,2]. In a meta-analysis consist-
ing of Caucasian populations, aspirin therapy reduced the
combined risk of myocardial infarction by 28% but had
no effect on total mortality and stroke [3]. Despite the
high risks for CVD in type 2 diabetes, most of the data
relating to the use of aspirin and anti-platelet agents in
diabetes come from post-hoc analysis of large clinical tri-
als with small numbers and insufficient statistical power
[4]. In a recent multicentre, placebo-controlled, rand-
omized trial, aspirin treatment with or without anti-oxi-
dant did not confer beneficial effects in diabetic patients
who had no clinical evidence of CVD [5].
In both primary and secondary prevention trials, aspirin
use is associated with a 2-fold increased risk for gastroin-
testinal (GI) bleeding and 80% increased risk of haemor-
rhagic stroke [4,6]. Besides, studies from Asian
populations suggest high rates of GI bleeding in patients
receiving aspirin (38.5% patients on aspirin had gastrodu-
odenal mucosal injury) [7]. This may in part explain the
relatively low rate of aspirin usage in Asian patients with
CVD or associated risk factors [8]. Other researchers have
reported higher rates of haemorrhagic stroke in Chinese
than their Caucasian counterparts (23-52% vs. 9-18% of
all strokes) [9,10]. In the CHARISMA Study which com-
pared dual therapy of clopidogrel plus aspirin versus pla-
cebo plus aspirin, a higher rate of primary end point (fatal
or non-fatal CVD) was observed in patients with multiple
risk factors including diabetes treated with dual therapy
(6.6%) than those treated with aspirin alone (5.5%) [11].
In light of the uncertain clinical effects of aspirin therapy
and relative paucity of data in diabetic patients, we under-
took a prospective analysis to examine the benefit (avoid-
ance of vascular events) and harm (occurrence of major
bleeding) of low-dose aspirin therapy (75 to 325 mg per
day) for primary and secondary prevention of CVD in
Chinese Type 2 diabetic patients.
Methods
Subjects
Type 2 diabetic patients aged 30 years or above were
selected from the Hong Kong Diabetes Registry estab-
lished since 1995. Using an electronic prescription data-
base, we identified patients who had received low-dose
aspirin (75-325 mg per day) [5] during the observational
period ("aspirin users") and those who had not ("non-
users"). For each subject, the index (baseline) date
referred to the date of enrolment to the Registry; or the
date of aspirin initiation if patients were started on aspirin
after the diabetes assessment. This avoided the error of
giving the aspirin users "immortal" person-time (i.e. the
error in overestimating the time to development of end-
point if the index date taken was earlier than the time
when aspirin was initiated) [12]. History of GI bleeding
was confirmed using databases of hospital admission and
endoscopy reports, dated back to 1995. Exclusion criteria
included known history of malignancy, haemorrhagic
stroke, upper GI bleeding, or any medical condition pre-
disposing to GI bleeding, including alcoholism, oesopha-
geal varices, Mallory-Weiss syndrome, liver cirrhosis or
coagulopathies [13], as recorded in the endoscopy
reports. The exclusion criteria were identified from dis-
charge diagnosis based on International Classification of
Diseases, Ninth Revision (ICD-9) codes, except for upper
GI bleeding for which endoscopy reports were used to
improve the sensitivity of event detection. The analysis of
the Registry was approved by the Clinical Research Ethics
Committee, the Chinese University of Hong Kong and
complied with the Declaration of Helsinki. All patients,
upon enrolment to the Registry, provided written
informed consent for data analysis and research purpose.
Hong Kong Diabetes Registry
The Hong Kong Diabetes Registry was established in 1995
for quality assurance and improvement purposes at the
Prince of Wales Hospital [14], which is a regional hospital
serving a 1.2 million population. All patients undergo a 4-
hour assessment modified from the European DIABCARE
protocol [15]. Once a diabetic subject had undergone the
comprehensive assessment, he/she was considered to
have entered this study cohort and would be followed up
till death.
Due to the heavily subsidized hospital care and less well
developed primary care system in Hong Kong, the major-
ity of patients with chronic diseases such as diabetes are
managed in public hospital clinics where medications are
dispensed on site. Since December 1996, all medication
history, laboratory results and discharge summaries had
been computerized and are available at the Hong Kong
Hospital Authority (HA) Headquarter which is the gov-
erning body of 41 public hospitals which account for 95%
hospital beds.
Primary and secondary prevention
The study population was stratified into the primary and
secondary prevention cohorts. The former was defined as
patients with no known history of occlusive vascular dis-
ease at enrolment. These included coronary heart disease
(CHD) defined as angina with positive stress test or imag-
ing, hospitalization with myocardial infarct (MI), stroke,
transient ischaemic attack (TIA), or peripheral vascular
disease (PVD) defined as history of lower extremity ampu-
tation, absent foot pulses confirmed by ankle:brachial
ratio less than 0.9 on Doppler ultrasound scan. The sec-
ondary prevention cohort was defined as patients with
known history of one or more of the above predefined
vascular diseases at baseline. Patients treated with nitrateCardiovascular Diabetology 2009, 8:57 http://www.cardiab.com/content/8/1/57
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at baseline were also included in the secondary preven-
tion cohort [16].
Clinical endpoints
Follow-up time was calculated as the period from enrol-
ment to the first CHD event, death or 30th July 2005,
whichever came first. Clinical endpoints were ascertained
using the computerised records of endoscopy, hospital
discharges and death as retrieved from the HA Central
Computer System. Primary and secondary endpoints were
defined to examine the potential benefit (in reducing
major vascular events) and harm (in causing upper GI
bleeding and haemorrhagic stroke) associated with aspi-
rin use. The "primary composite endpoint" was defined as
a combination of death from a vascular cause and major
vascular events, including hospitalizations due to non-
fatal MI and/or non-fatal stroke, whichever occurred ear-
lier. Vascular causes included cardiac, cerebrovascular,
venous thromboembolic, haemorrhagic, and other vascu-
lar causes, in accordance with the meta-analysis by the
Antithrombotic Trialists' Collaboration [17].
"Secondary endpoints" included upper GI bleeding and
haemorrhagic stroke. Since upper GI bleeding is a non-
specific diagnosis which can be due to oesophagitis,
varices, and malignancy in addition to gastroduodenal
ulcer, we defined ulcer bleeding based on the endoscopy
reports which are computerized in all HA hospitals.
Hence, ulcer bleeding was defined as gastric or duodenal
ulcer presented as haematemesis, melena, or coffee
ground vomiting as documented in the upper GI endos-
copy reports by gastroenterologist [18]. All patients
admitted with suspected stroke underwent computer tom-
ography (CT) scan imaging to distinguish haemorrhagic
from ischaemic stroke according to HA clinical guidelines
[19].
The occurrence of vascular endpoints was identified from
the principal discharge diagnoses using the ICD-9 codes
including fatal or non-fatal CHD (codes 410-414); con-
gestive heart failure (code 428), all stroke [fatal or non-
fatal] (codes 430-438), haemorrhagic stroke (codes 430-
432), ischaemic stroke (codes 433-435) or coronary revas-
cularization (codes 36.0-36.1). CHD was defined as MI
(code 410) or ischemic heart disease (code 411-414).
Sample size estimation
In a pilot analysis of 5,000 patients enrolled in the Hong
Kong Diabetes Registry [20], amongst aspirin non-users,
the primary annual CVD event rate was 2.5% and 10%
amongst those with prior history of CVD. For a 10-year
observational study and assuming a 25% risk reduction
with aspirin [5], 5,000 patients would be required to
achieve 80% power at a 5% two-sided, alpha level based
on the proportional hazards model for the primary pre-
vention analysis and 900 patients for secondary preven-
tion analysis.
Statistical analysis
Analyses were performed using the Statistical Package for
Social Sciences (SPSS, version 14.0) software. All data are
expressed as mean ± standard deviation (SD), median
(interquartile range IQR) or geometric mean (95% confi-
dence interval [CI]) as appropriate. Serum triglyceride
(TG) and creatinine, and spot urine albumin-creatinine
ratio (ACR) were logarithmically transformed due to
skewed distributions. Chi-square (χ2) test and Student's t-
test were used for between-group comparisons, as appro-
priate. Cox proportional hazards models were used to cal-
culate the hazard ratios (HR) with 95% CI for the primary
and secondary endpoints associated with aspirin use. For
each of the outcome measures, Kaplan-Meier procedure
was used to estimate the survival curves for aspirin users
and non-users. The proportional hazards assumption was
checked by examining the plots of the hazard functions
for each group. The primary composite endpoint and its
components were analysed separately for the primary and
secondary prevention cohorts.
Multivariable techniques were used to control for poten-
tial confounders including age, gender, smoking habit,
alcohol intake, duration of diabetes, retinopathy, sensory
neuropathy, PVD, history of CVD, body mass index,
blood pressure (BP), serum lipids, glycated haemoglobin
(HbA1c), albuminuria, serum creatinine, and usage of
antihypertensive, antidiabetic, anticoagulant, and lipid-
lowering drugs at baseline. For the analysis of GI bleeding,
the usage of nonsteroidal anti-inflammatory drugs, corti-
costeroids, and acid-suppressing agents were included as
covariates to adjust for potential confounding effects [21].
A p value < 0.05 (2-tailed) was considered significant.
Results
Demographics
Figure 1 summarises the patients included in the final
analysis. From the original database of 6454 patients,
5731 patients (age: 58.0 ± 12.8 years; disease duration:
8.1 ± 6.9 years) entered the primary prevention cohort
and 723 patients, secondary prevention cohort. The per-
centage of aspirin usage was 18% (n = 1034) and 81% (n
= 585) in the secondary prevention cohort. The mean fol-
low-up time from baseline to death or study end (July
2005) was 4.6 ± 2.5 years (median [IQR]: 4.7 [4.4] years),
giving a total of 29,618 person-years of follow-up. In both
the primary and secondary cohorts, aspirin users had
more adverse cardio-metabolic risk profiles, increased
usage of cardiovascular drugs, anti-diabetic drugs and his-
tamine H2  receptor blockers than aspirin non-users
(Tables 1, 2).Cardiovascular Diabetology 2009, 8:57 http://www.cardiab.com/content/8/1/57
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Clinical endpoint of vascular outcomes and major 
gastrointestinal bleeding
In the primary prevention cohort, the primary composite
endpoint occurred more frequently in aspirin users
(13.3%, n = 138) than in non-users (5.5%, n = 260)
(Table 3). Vascular death also occurred more frequently in
aspirin users (5.2%, n = 54) than in non-users (1.3%, n =
61). A similar trend was observed for non-fatal MI (aspirin
users, 2.6%, n = 27; non-users, 0.9%, n = 40) and non-
fatal stroke (users, 6.9%, n = 71; non-users, 3.8%, n =
180). In the secondary prevention cohort, there were 145
primary composite endpoint with 116 (19.8%) events in
users and 29 (21%) in non-users of aspirin. Vascular
death occurred in 55 (9.4%) aspirin users and 14 (10.1%)
non-users. Non-fatal MI occurred in 20 (3.4%) aspirin
users and 3 (2.2%) non-users. Non-fatal stroke occurred
in 55 (9.4%) aspirin users and 18 (13%) non-users. The
event rates were higher in non-users except for non-fatal
MI, albeit not significant.
On multivariable analysis, aspirin use was associated with
a 2-fold increased risk for the primary endpoint in the pri-
mary cohort (Table 3). The significance persisted with
subgroup analysis by gender: HR (95% CI) = 1.86 (1.36,
2.54), men (n = 2560); 2.32 (1.70, 3.17), women (n =
3171) and 2.07 (1.66, 2.59), all (n = 5731). There were
significant risk associations of aspirin with vascular death
and non-fatal MI but not non-fatal stroke (Table 3). In the
secondary prevention cohort, these risk associations were
not observed (Figure 2 and Table 3). The primary compos-
ite endpoint in secondary prevention cohort remained
insignificant after adjustment of gender. In the entire
cohort of 6,454 patients, the rates of upper GI bleeding
and endoscopically-confirmed ulcer bleeding were higher
in aspirin users than non-users (Figure 3). There was also
a trend for increased risk of haemorrhagic stroke in aspirin
users than non-users, albeit not significant.
Discussion
Cardiovascular events are major causes of mortality and
morbidity in type 2 diabetes. Using this comprehensive
Diabetes Registry, we have reported an annual CVD event
rate averaging 2-3% increasing to 10% in those with car-
dio-renal complications at enrolment [14]. In the present
Table 1: Baseline clinical and biochemical characteristics between aspirin users and non-users in the complete cohort (n = 6,454)
Overall
(n = 6,454)
Aspirin users
(n = 1,619)
Non-aspirin users
(n = 4,835)
p-value‡
Age, years 58.0 ± 12.8 65.7 ± 10.2 55.4 ± 12.6 < 0.001
Male, n (%) 2,928 (45.4) 819 (50.6) 2,109 (43.6) < 0.001
Duration of diabetes, years 8.1 ± 6.9 11.4 ± 7.5 7.0 ± 6.3 < 0.001
Smoking (current), n (%) 1,033 (16.1) 253 (15.7) 780 (16.2) < 0.001
Alcohol (current), n (%) 517 (8.1) 100 (6.2) 417 (8.7) < 0.001
Systolic blood pressure, mmHg 136.2 ± 20.3 142.6 ± 21.7 134.1 ± 19.4 < 0.001
Diastolic blood pressure, mmHg 75.1 ± 10.6 75.1 ± 11.2 75.1 ± 10.3 0.848
Body weight, kg 63.4 ± 12.3 63.3 ± 11.8 63.5 ± 12.5 0.583
Body mass index, kg/m2 25.2 ± 3.9 25.3 ± 3.7 25.2 ± 4.0 0.135
Waist circumference (cm): Males 88.7 ± 9.6 90.1 ± 8.7 88.4 ± 9.8 < 0.001
Females 83.8 ± 10.0 85.5 ± 9.9 83.6 ± 9.9 < 0.001
Glycosylated haemoglobin, % 7.59 ± 1.69 7.72 ± 1.68 7.57 ± 1.69 < 0.001
Fasting plasma glucose, mmol/L 8.59 ± 3.10 8.57 ± 3.18 8.59 ± 3.09 0.046
Total cholesterol, mmol/L 5.21 ± 1.05 5.09 ± 1.06 5.23 ± 1.05 0.167
LDL cholesterol, mmol/L 3.19 ± 0.95 3.06 ± 0.97 3.21 ± 0.94 0.286
HDL cholesterol, mmol/L 1.30 ± 0.38 1.26 ± 0.33 1.31 ± 0.39 < 0.001
Serum triglycerides, mmol/L † 1.45 (1.43, 1.47) 1.58 (1.53, 1.64) 1.43 (1.41, 1.45) < 0.001
Serum creatinine, μmol/L † 83.2 (82.4, 83.9) 97.1 (95.0, 99.2) 79.1 (78.3, 79.8) < 0.001
Estimated GFR# 74.6 (73.8, 75.3) 58.6 (56.8, 60.5) 77.6 (76.8, 78.5) < 0.001
Spot urine ACR, mg/mmol † 3.7 (3.6, 3.9) 8.3 (7.4, 9.2) 2.9 (2.7, 3.0) < 0.001
Blood haemoglobin, g/dL 13.7 ± 1.6 13.4 ± 1.7 13.8 ± 1.6 < 0.001
Peripheral vascular disease, n (%) 400 (6.2) 223 (13.8) 177 (3.7) < 0.001
Lower extremity amputation, n (%) 26 (0.4) 13 (0.8) 13 (0.3) 0.003
Ischaemic heart disease, n (%) 281 (4.4) 240 (14.8) 41 (0.8) < 0.001
Myocardial infarction, n (%) 67 (1) 65 (4) 2 (0) < 0.001
Coronary revascularisation, n (%) 77 (1.2) 75 (4.6) 2 (0) < 0.001
Congestive heart failure, n (%) 119 (1.8) 85 (5.3) 34 (0.7) < 0.001
Stroke, n (%) 256 (4) 221 (13.7) 35 (0.7) < 0.001
Atrial fibrillation, n (%) 70 (1.1) 35 (2.2) 35 (0.7) < 0.001
Mean ± SD or number of patients (%) or † geometric mean (95% confidence interval).
‡ By Chi-square test for categorical variables and t-test for continuous variables
#Based on the abbreviated MDRD (Modification of Diet in Renal Disease) equation for Chinese (ref. 42)
LDL and HDL = low- and high-density lipoprotein, ACR = albumin-to-creatinine ratio, GFR = glomerular filtration rate.Cardiovascular Diabetology 2009, 8:57 http://www.cardiab.com/content/8/1/57
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analysis, the overall aspirin usage was 18% in the primary,
and 80% in the secondary prevention cohort. During a 5-
year observational period, aspirin use was associated with
increased risk of CVD events and related death in the pri-
mary prevention cohort. In the secondary prevention
cohort, similar event rates were observed between aspirin
users and non-users. In the entire cohort, there was
increased risk of hemorrhagic stroke and GI bleeding in
the aspirin users.
Clinical guidelines in the United State recommend aspirin
use for secondary prevention in type 2 diabetic patients
with history of CVD and for primary prevention in those
with a 10-year CHD risk of 15% or more [22]. However,
these recommendations were not supported by evidence
since most of the data in diabetic patients came from post-
hoc analysis of large trials with marked heterogeneity
[5,17,23,24]. In the meta-analysis by the Antiplatelet Tri-
alists' Collaboration, only 6.5% of 68,814 study subjects
with history of CVD had diabetes [5]. In primary preven-
tion trials, the proportion of diabetic subjects was only 2-
17% [23,24]. In a recent multicentre, randomised, pla-
cebo-controlled study with 1276 type 1 or type 2 diabetic
patients who had no clinical evidence of CHD or PVD,
aspirin treatment with or without anti-oxidants did not
confer benefits on death or CVD event rates [5].
In our study, apart from lack of benefits, we observed a
paradoxical increase in vascular risk amongst aspirin users
in the primary prevention cohort. These findings are in
Table 2: Baseline patterns of drug usage between users and non-users of aspirin in the complete cohort (n = 6,454).
Overall
(n = 6,454)
Aspirin users
(n = 1,619)
Non-aspirin users
(n = 4,835)
p-value†
Anti-diabetic drugs
Insulin 1,203 (18.6%) 458 (28.3%) 745 (15.4%) < 0.001
Any oral agent 4,301 (66.6%) 1,128 (69.7%) 3,173 (65.6%) 0.003
Sulphonylurea 3,461 (53.6%) 928 (57.3%) 2,533 (52.4%) 0.001
Metformin 3,189 (49.4%) 839 (51.8%) 2,350 (48.6%) 0.025
Thiazolidinedione 27 (0.4%) 9 (0.6%) 18 (0.4%) 0.322
Anti-hypertensive drugs
Any anti-hypertensive drugs 3,103 (48.1%) 1,135 (70.1%) 1,968 (40.7%) < 0.001
Number of anti-hypertensive drugs* 0.8 ± 1.0 1.3 ± 1.1 0.6 ± 0.9 < 0.001
Any RAS inhibitor 1,632 (25.3%) 615 (38%) 1,017 (21%) < 0.001
ACE inhibitor 1,519 (23.5%) 564 (34.8%) 955 (19.8%) < 0.001
AII antagonist 123 (1.9%) 57 (3.5%) 66 (1.4%) < 0.001
Thiazide or related diuretic 162 (2.5%) 61 (3.8%) 101 (2.1%) < 0.001
Loop diuretic 217 (3.4%) 129 (8%) 88 (1.8%) < 0.001
Beta-blocker 756 (11.7%) 386 (23.8%) 370 (7.7%) < 0.001
Alpha-blocker 189 (2.9%) 83 (5.1%) 106 (2.2%) < 0.001
Calcium channel blocker 1,838 (28.5%) 697 (43.1%) 1,141 (23.6%) < 0.001
Centrally-acting agent 309 (4.8%) 117 (7.2%) 192 (4%) < 0.001
Vasodilator 19 (0.3%) 12 (0.7%) 7 (0.1%) < 0.001
Other cardiovascular drugs
Statin 902 (14%) 434 (26.8%) 468 (9.7%) < 0.001
Fibrate 232 (3.6%) 76 (4.7%) 156 (3.2%) 0.006
Digoxin 65 (1%) 33 (2%) 32 (0.7%) < 0.001
Anti-arrhythmic drug 20 (0.3%) 9 (0.6%) 11 (0.2%) 0.040
Oral anticoagulant 59 (0.9%) 9 (0.6%) 50 (1%) 0.080
Antiplatelet drug other than aspirin 24 (0.4%) 14 (0.9%) 10 (0.2%) < 0.001
Other drugs
NSAID 157 (2.4%) 46 (2.8%) 111 (2.3%) 0.218
Oral corticosteroid 83 (1.3%) 19 (1.2%) 64 (1.3%) 0.643
Proton pump inhibitor 25 (0.4%) 10 (0.6%) 15 (0.3%) 0.085
Histamine H2-receptor antagonist 191 (3%) 87 (5.4%) 104 (2.2%) < 0.001
Misoprostol 1 (0%) 0 (0%) 1 (0%) 0.563
Data are number of patients (%) or mean ± SD
† By Chi-square test for categorical variables and t-test for continuous variables
RAS = renin-angiotensin system, ACE = angiotensin-converting enzyme, AII = angiotensin II, NSAID = non-steroidal anti-inflammatory drug, RAS 
inhibitor = either an ACE inhibitor or AII antagonistCardiovascular Diabetology 2009, 8:57 http://www.cardiab.com/content/8/1/57
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agreement with current literature. In a subgroup analysis
of the Antiplatelet Trialists' Collaboration which included
data from diabetic patients (n = 1,365), the CVD event
rates was 4.9% in aspirin users and 4.4% in aspirin non-
users [5]. In our analysis, the non-fatal MI and stroke rates
were 2.6% and 6.9% in aspirin users and the respective
rates were 0.9% and 3.8% in aspirin non-users. In the Col-
laborative Group of the Primary Prevention Project which
has the highest proportions of aspirin-treated diabetic
patients [23,24], aspirin was associated with a non-signif-
icant increase in CVD deaths (RR [95% CI]: 1.23 [0.69 to
2.19]) in diabetic patients, as compared to a significant
68% reduction in aspirin-treated, non-diabetic subjects
[25].
In our secondary prevention cohort, aspirin use was asso-
ciated with a non-significant 9% reduction in vascular
events. This lack of significance may be due to insufficient
sample size (n = 723), when 900 patients are required to
give the analysis an 80% statistical power. However, the
very similar event rates between aspirin users (22.2%) and
non-users (25.4%) strongly suggest a lack of benefit of
aspirin. In the first meta-analysis performed in 1994 by
the Antiplatelet Trialists' Collaboration involving 4502
Patients included into the final analysis according to the inclusion and exclusion criteria Figure 1
Patients included into the final analysis according to the inclusion and exclusion criteria.
Patients enrolled in the Diabetes Registry (1995-2005)
n=7,920
Exclusion:
(1) Computerized drug data only available after 1996, n=582;
(2) Patients of non-Chinese ethnicity and/or age <30 years at 
baseline, n=291:
- non-Chinese, n=51; and/or
- age <30 years, n=252
(3) Other diseases, n=593:
- type 1 diabetes, n=191;
- known malignancy or other terminal illnesses, n=166;
- history of hemorrhagic stroke, n=21;
- upper gastro-intestinal bleeding, n=156;
- alcoholism, n=8;
- oesophageal bleeding, n=20;
- Mallory Weiss syndrome, n=10;
- Liver cirrhosis, n=86; and/or
- Coagulopathy, n=1
6,454 patients entered into final analysis
Primary prevention cohort
n=5,731
Secondary prevention cohort
n=723Cardiovascular Diabetology 2009, 8:57 http://www.cardiab.com/content/8/1/57
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diabetic patients and 42,323 non-diabetic subjects in the
secondary prevention cohort, anti-platelet therapy mod-
estly reduced the risk of vascular events by 3.8% in both
groups (from 22.3% to 18.5% in diabetic group and from
16.4% to 12.6% in non-diabetic group, p < 0.001 in both
groups) (5). In 2002, the same group performed a second
meta-analysis of a larger cohort of 135,000 subjects. In a
sub-group analysis of 9 trials which included 4,961 dia-
betic patients, antiplatelet therapy was associated with a
non-significant 7% reduction in serious vascular events
[17].
Aspirin and bleeding complications
Aspirin therapy is associated with elevated risks of major
bleeding. Aspirin may also increase risk of haemorrhagic
stroke [26], which carries poor prognosis [27]. Several
lines of evidence suggest that Asian including Chinese
patients have higher prevalence of GI bleeding and haem-
orrhagic stroke than their Caucasian counterparts. In a
hospital-based survey involving Hong Kong Chinese, GI
bleeding accounted for 37% of all adverse drug reactions
leading to admissions [28] compared to 6.0-14.5%
reported elsewhere [29]. In Mainland China, a stroke sur-
veillance program also reported a higher age-adjusted
stroke incidence (Chinese vs. Caucasians: 480-800 vs.
440-650 per 100,000 person-years) and intracerebral
haemorrhage (160-450 vs. 40-120 per 100,000 person-
years) in Chinese aged ≥ 55 years as compared to Cauca-
sians [30].
In our cohort, usage of low-dose aspirin was associated
with a 2.2-fold increased risk of upper GI bleeding. When
we restricted the analyses to endoscopically-confirmed
ulcer bleeding, we still observed an adjusted 72%
increased risk amongst aspirin users. Other researchers
have reported 1.5-2.6 increased risk of upper GI bleeding
or perforation with aspirin use at daily dosage less than
300 mg [4,13]. It remains to be proven whether this high
rate of GI bleeding might have confounded the increased
risk of CVD in the primary prevention cohort and that
treatment non-compliance may have contributed to the
lack of benefits of aspirin in secondary prevention. In our
limited analysis, use of other drugs such as NSAID was not
found to be associated with clinical events though the
observational nature of this study precludes any conclu-
sion.
Apart from GI bleed, there was a non-significant 70%
increased risk of haemorrhagic stroke amongst aspirin
users (p = 0.051) probably due to insufficient sample size.
This is similar to a reported risk of 84% in a meta-analysis
of low dose aspirin (average daily dosage of 273 mg) in
Caucasian patients [6]. The absolute risk of haemorrhagic
stroke associated with aspirin appeared to be higher in
Table 3: Event rates and adjusted hazard ratio (95% confidence interval, CI) for clinical endpoints using multivariable Cox regression 
analysis in 6454 type 2 diabetic patients stratified by use of aspirin for primary or secondary prevention of cardiovascular disease.
Overall Aspirin users Non-aspirin users Hazard ratio*
(95% CI)
p-value†
Primary prevention cohort: n = 5,731 n = 1,034 n = 4,697 - -
Primary composite endpoint 398 (6.9%) 138 (13.3%) 260 (5.5%) 2.07 (1.66 to 2.59) < 0.001
Vascular death 115 (2%) 54 (5.2%) 61 (1.3%) 2.61 (1.70 to 4.01) < 0.001
Non-fatal myocardial infarct 67 (1.2%) 27 (2.6%) 40 (0.9%) 2.05 (1.11 to 3.79) 0.023
Non-fatal stroke 251 (4.4%) 71 (6.9%) 180 (3.8%) 1.52 (1.14 to 2.04)# 0.005#
Secondary prevention cohort: n = 723 n = 585 n = 138 - -
Primary composite endpoint 145 (20.1%) 116 (19.8%) 29 (21%) 0.91 (0.60 to 1.37)# NS
Vascular death 69 (9.5%) 55 (9.4%) 14 (10.1%) 0.92 (0.51 to 1.69)# NS
Non-fatal myocardial infarct 23 (3.2%) 20 (3.4%) 3 (2.2%) 1.42 (0.42 to 4.85)# NS
Non-fatal stroke 73 (10.1%) 55 (9.4%) 18 (13%) 0.71 (0.42 to 1.23)# NS
Complete cohort: n = 6,454 n = 1,619 n = 4,835 - -
Upper gastrointestinal bleeding 138 (2.1%) 70 (4.3%) 68 (1.4%) 2.19 (1.53 to 3.15) < 0.001
Endoscopically-confirmed ulcer bleeding 68 (1.1%) 33 (2%) 35 (0.7%) 1.72 (1.02 to 2.91) 0.043
Haemorrhagic stroke 61 (0.9%) 25 (1.5%) 36 (0.7%) 1.71 (1.00 to 2.95)# 0.051#
Data are number (%) of patients
Primary composite endpoint was defined as the composite of vascular death, non-fatal myocardial infarct or non-fatal stroke in accordance with the 
definition adopted by the Antiplatelet Trialists' Collaboration. Endpoints were identified from the principal diagnosis and principal procedure using 
the ICD-9 codes.
*Multivariable Cox proportional hazards model with age, gender, smoking, alcohol, duration of diabetes, retinopathy, sensory neuropathy, 
peripheral vascular disease, cardiovascular history, body mass index, blood pressure, serum lipids, HbA1c, albuminuria, serum creatinine, and 
baseline usage of antihypertensive, antidiabetic, anticoagulant, and lipid-lowering drugs adjusted as covariates.
#Hazard ratios and p-values were from univariate analysis.Cardiovascular Diabetology 2009, 8:57 http://www.cardiab.com/content/8/1/57
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Chinese than Caucasians (3.2 vs. 1.2 additional events per
1,000 person-years treated) [6].
Limitations
Our results need to be interpreted with caution. Firstly,
our study did not distinguish between patients who
received plain or enteric-coated aspirin although most
studies suggested similar risks of GI bleed with different
aspirin formulations [13,31,32]. Secondly, in agreement
with most studies [13], we combined both cohorts in our
analysis due to their similar risks of GI bleeding. Thirdly,
there are considerable variations in the definitions of
upper GI bleeding which may confound the risk estima-
tion although we have used endoscopy reports to identify
cases of ulcer bleeding.
While our overall results are in line with the literature,
there is inevitable selection bias inherent with observa-
tional studies. Nevertheless, our comprehensive database
has probably provided the largest unselected cohort of
diabetic patients with relatively long duration of follow-
up to address this unresolved therapeutic question. The
detailed clinical and drug information including hospital-
ization and endoscopy reports have enabled us to adjust
for confounding factors to draw important conclusions
which have implications on clinical management. Our
findings, which are particularly relevant to Chinese, may
also explain the relatively low usage of aspirin in Asians
than Caucasians [8]. Although we have not systemically
examined doctors' rationale of prescribing, clinical experi-
ences with adverse effects of aspirin may have led to cau-
tious use of this class of drug.
Conclusion and Implications
The baseline data of our cohort showed the aspirin users
had more risk factors for CVD than non-users. After statis-
tical analysis with adjustment of these variables, aspirin
use, among Chinese type 2 diabetic patients, for primary
prevention was associated with 74% increased risk of inci-
dent CVD events while no benefit was observed in the sec-
ondary prevention cohort. This conclusion needs
prospective study to be confirmed. In addition, overall
Adjusted Kaplan-Meier curves for the primary composite endpoint (vascular death, non-fatal myocardial infarction and non- fatal stroke) in the primary and secondary prevention cohorts, stratified by aspirin usage during the observational period Figure 2
Adjusted Kaplan-Meier curves for the primary composite endpoint (vascular death, non-fatal myocardial inf-
arction and non-fatal stroke) in the primary and secondary prevention cohorts, stratified by aspirin usage dur-
ing the observational period.
(b) Secondary prevention cohort (n=723) (a) Primary prevention cohort (n=5,731)
p-value: <0.001 p-value: <0.001Cardiovascular Diabetology 2009, 8:57 http://www.cardiab.com/content/8/1/57
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speaking, aspirin use was associated with a 2.2-fold
increased risk of upper GI bleeding and a non-significant
trend for increased risk of haemorrhagic stroke. These
results are not incompatible with the current body of
knowledge based on either meta-analyses or randomized
clinical trials and call for re-evaluation of the current rec-
ommendation regarding the use of aspirin in diabetic
patients. Given their multiple comorbidities and high risk
for CVD, there is an urgent need to design studies to eval-
uate the risk-benefit equation regarding the use of aspirin
and other anti-platelet agents in diabetic patients with
detailed documentation of potential confounders. In this
respect, silent GI bleed with aspirin therapy may lead to
anaemia which is a major predictor for CVD events in Chi-
nese type 2 diabetic patients [33]. Meanwhile, there is a
need to draw up protocols to identify high risk subjects for
GI bleeding (e.g. smokers and carriers of Helicobacter
Pyloris) for co-administration of ulcer-healing drugs, to
maximize benefits and minimize harm associated with
aspirin therapy.
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